Helicobacter Pylori Infection Testing

Covered: testing for H. pylori is supported for evaluation of new‑onset dyspepsia in patients <60 years with ≤1 nonprogressive alarm symptom, for persistent dyspepsia after 2 weeks of appropriate H. pylori antibiotics, before starting PPI therapy, as part of preoperative bariatric evaluation, and for suspected reinfection. Excluded: AmHPR NGS antibiotic‑resistance panel, H. pylori serology, IL‑1B polymorphism testing, plasma pepsinogen II for eradication assessment, and urine anti‑H. pylori IgG are considered experimental/investigational and not covered.

"Confirmation of the presence of the H. pylori bacterium can be determined non-invasively using an FDA-cleared urea breath test or a stool antigen test or invasively on endoscopic biopsy followed by..."

Sign up to see full coverage criteria, indications, and limitations.